Publications IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn’s disease? Citation Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? Best Pract Res Clin Gastroenterol. 2019 Feb-Apr;38-39:101604. doi: 10.1016/j.bpg.2019.02.006. Epub 2019 Feb 19. PMID: 31327402. Abstract The interleukin (IL)-12 family of cytokines, including IL12 and IL 23, play an important role in driving aberrant Th1 and Th17 immune responses in patients with Crohn’s disease (CD). Tags Brazikumab, Crohn's Disease, Guselkumab, Mirikizumab, Pathology, Rizankizumab, Therapy, Ustekinumab Read More
